Sanofi Hits M&A Trail Again To Buy UK's KyMab

Gets Hold Of Gets Mid-Stage Atopic Dermatitis Drug

Another UK biotech has been swallowed up by a big pharma with Sanofi acquiring the Cambridge-based firm in a deal that could be worth almost $1.5bn.

Sanofi_France
Sanofi spends big to buy Kymab • Source: Shutterstock

More from Deals

More from Business